NCT06149494 is a Phase 2 clinical trial of Vapendavir in COPD Exacerbation Acute, sponsored by Altesa Biosciences, Inc..

Who is sponsoring NCT06149494?

NCT06149494 is sponsored by Altesa Biosciences, Inc..

What drugs are being tested in NCT06149494?

Interventions in NCT06149494: Vapendavir, Placebo.

What condition does NCT06149494 study?

NCT06149494 studies COPD Exacerbation Acute, COPD With Acute Lower Respiratory Infection, Rhinovirus, Virus Diseases, Virus Infection, RNA, Enterovirus, Enterovirus Infections, Rhinovirus Infection, Infection Viral, Respiratory Complication, Respiratory Disease, Respiratory Tract Infections, Respiratory Tract Diseases, Respiratory Viral Infection, Upper Resp Tract Infection, Upper Respiratory Tract Infections, Upper Respiratory Disease, Upper Respiratory Disorder, Upper Respiratory Disease, Acute, Upper Respiratory Infection Viral, Infections, Respiratory, Infections, Copd, Viral Infection, Emphysema or COPD, Lower Respiratory Disease, Lower Respiratory Disorder, Lower Respiratory Tract and Lung Infections, Pulmonary Disease, Pulmonary Disease, Chronic Obstructive, Respiratory Disease Chronic, Lung Diseases, Lung Disease Chronic, Obstructive Pulmonary Disease, Chronic Lower Respiratory Diseases, Chronic Respiratory Disease.

Is NCT06149494 still recruiting?

NCT06149494 is currently completed. Last updated 30 September 2025.

Last reviewed 2025-09-30 · How we verify

NCT06149494

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection

Completed Phase 2 Last updated 30 September 2025

What this trial tests

Phase 2 trial testing Vapendavir in COPD Exacerbation Acute in 52 participants. Completed in 30 March 2025.

Timeline

20 November 2023

Primary endpoint
30 March 2025

30 March 2025

Quick facts

Lead sponsor	Altesa Biosciences, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	52
Start date	20 November 2023
Primary completion	30 March 2025
Estimated completion	30 March 2025
Sites	1 location across United Kingdom

Drugs / interventions tested

Vapendavir — full drug profile →
Placebo

Conditions studied

COPD Exacerbation Acute — all drugs for COPD Exacerbation Acute →
COPD With Acute Lower Respiratory Infection — all drugs for COPD With Acute Lower Respiratory Infection →
Rhinovirus — all drugs for Rhinovirus →
Virus Diseases — all drugs for Virus Diseases →

Sponsor

Altesa Biosciences, Inc.

Who can join

Adults 40 to 75, any sex, with COPD Exacerbation Acute or COPD With Acute Lower Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Vapendavir (VPV) is a drug being developed to treat human rhinovirus (RV) infection, one virus responsible for the common cold. Vapendavir prevents the virus from entering cells and making more infectious copies of itself. A study is being planned to investigate VPV in patients with chronic obstructive pulmonary disease (COPD, a lung disease making it difficult to breathe) who develop a rhinoviral infection; however, VPV has not been approved for use in treating any indication (disease) by the FDA or any other global regulatory agency. Therefore, VPV is considered investigational, and the study doctor is conducting this investigational research study. Safety will be monitored throughout the entire study.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The common cold: The need for an effective treatment amid the FDA discussion on oral phenylephrine.
Išerić E, Verster JC. · · 2024 · cited 2× · PMID 39253103 · DOI 10.1016/j.jacig.2024.100318
A clinical SARS-CoV-2 Mpro inhibitor blocks replication of multiple enteroviruses and confers oral in vivo protection in animal models.
Ye Z, Dai W, Zhang S, Xiang Y, et al · · 2026 · PMID 41811867 · DOI 10.1371/journal.ppat.1014051

Verify or expand the search:

Other trials of Vapendavir

Trials testing the same drug.

NCT06834295 — A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]Vapendavir · Phase 1, PHASE2 · completed
NCT05962645 — Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD · Phase 1 · completed

Other recruiting trials for COPD Exacerbation Acute

Currently open trials in the same condition.

NCT05703919 — Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease · Phase 4 · recruiting
NCT06274957 — The Effect of Airway and Chest Wall Oscillation on Respiratory Functions in COPD Patients in Acute Exacerbation · NA · recruiting
NCT06331416 — Multiparametric Home Telemonitoring of Patients With Chronic Obstructive Pulmonary Disease Exacerbation · NA · recruiting
NCT05452226 — Neuromuscular Electrical Stimulation in COPD/Community Acquired Pneumonia · NA · recruiting
NCT05568043 — The Reducing REVISITS Study: A Cluster RCT · NA · recruiting

Other Altesa Biosciences, Inc. trials

Trials by the same sponsor.

NCT06834295 — A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]Vapendavir · Phase 1, PHASE2 · completed
NCT05962645 — Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06149494 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Altesa Biosciences, Inc.
Last refreshed: 30 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06149494.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing